2025年4月28日，ST三圣发布了2024年年报。报告显示，公司全年实现营业总收入11.96亿元，同比下降 41.10%；归属净利润亏损6.50亿元，扣非净利润亏损7.39亿元，同比分别下降43.82%和73.13%。尽管公 司在建材化工和医药制造两大业务板块中拥有一定的市场地位，但受市场需求萎缩、原材料价格上涨及 环保成本增加等多重因素影响，业绩持续承压。 ST三圣近五年营业总收入变化 35 30 25.5 24.89 25 20.77 20.3 单位（亿元） 11.96 10 5 0 2020年 2021年 2022年 2023年 2024年 ST三圣近五年归母净利润变化 5 - 0.73 单位（亿元） -3.18 -3.33 建材化工板块：市场需求萎缩，供应链受挫 在人才培养方面，ST三圣通过校招和社招的方式，为公司注入了新的活力，并建立了年度管理者绩效 考评体系，以优化管理团队的结构和效能。同时，公司持续投入研发创新，以技术引领为核心，推动产 品和服务的升级，为未来的市场复苏奠定基础。 尽管2024年ST三圣的业绩表现不佳，但公司通过一系列战略调整和管理优化，为未来的发展奠定了基 础。然而，市场需求 ...

第一财经每日精选最热门大公司动态。 【今日推荐】 美的格力都说自己是"空调第一名"， 数据提供方：引用数据为不同维度 4月27日晚间，美的集团和格力电器分别发布各自的2024年年度报告。在双方的财报中，美的集团 的表述为，"2024年，美的集团在家用空调等9个品类在国内线上与线下市场份额均列行业第一"；而 格力电器的表述为，"2024年格力品牌家用空调线上零售额份额为25.40%，位居行业第一"。针对两 家公司上述表述，引发许多股民和消费者质疑。对此，两家公司财报的数据提供方奥维云网回应媒体 称，两家公司财报引用数据维度有所不同。 时隔十年，小米再度登顶 库克对苹果AI进展失望？再次重组团队 据业内消息，库克已经将苹果的机器人团队转移至该公司的硬件部门，该部门由苹果高管约翰·特努 斯领导。在苹果智能（Apple Intelligence）功能推迟发布以来，库克一直在努力重组部分团队，例 如将Siri团队移交给苹果VisionPro部门主管迈克·罗克韦尔领导。最新的重组也暗示库克对该公司人 工智能和机器学习主管约翰·詹南德雷亚的失望。 赛力斯向港交所提交上市申请书 据港交所文件，赛力斯集团股份有限公司向港交所提 ...

Mergers and Acquisitions - Fushun Special Steel plans to absorb and merge its wholly-owned subsidiary Fushun Xinxing Steel Plate Co., Ltd, aiming to optimize management structure, reduce management costs, and improve operational efficiency [1] - Shenghang Co., Ltd. has completed the acquisition of 25.2762% of Shenghang Haoyuan's shares, now holding a total of 78.3316% of the company [2] - Yuanshang Co., Ltd. has completed the industrial and commercial change registration for the acquisition of 60% of Wuhan Hechuan You's shares [3] Earnings Disclosure - Sinopec reported Q1 2025 revenue of 735.36 billion yuan, a decrease of 6.9% year-on-year, with a net profit of 13.26 billion yuan, down 27.6% [4] - Yunnan Baiyao achieved Q1 2025 revenue of 10.841 billion yuan, a year-on-year increase of 0.62%, with a net profit of 1.935 billion yuan, up 13.67% [5] - Haitian Flavor Industry reported Q1 2025 revenue of 8.315 billion yuan, an increase of 8.08%, and a net profit of 2.202 billion yuan, up 14.77% [6] - CICC reported Q1 2025 revenue of 5.721 billion yuan, a significant increase of 47.69%, with a net profit of 2.042 billion yuan, up 64.85% [7] Share Buybacks - China Nuclear Power plans to repurchase shares worth between 300 million and 500 million yuan, with a maximum price of 13.98 yuan per share [8] - Yituo Co., Ltd. intends to repurchase up to 10% of its issued H shares, using self-owned and raised funds [9] - Xingguang Co., Ltd.'s actual controller plans to increase shareholding by no less than 10 million yuan and no more than 20 million yuan within three months starting from April 29, 2025 [10] - Haiou Co., Ltd. plans to repurchase shares worth between 60 million and 120 million yuan, with a maximum price of 17 yuan per share [11] Risk Matters - Lifang Shuke received a notice from the CSRC regarding an investigation into suspected information disclosure violations [12] - Boda Co., Ltd. will implement a delisting risk warning starting April 30 due to negative net profit and revenue below 300 million yuan [13] - Sitong Co., Ltd. will also face a delisting risk warning starting April 30 for similar financial issues [14] - Yuanshang Co., Ltd. will implement a delisting risk warning starting April 30 due to negative financial results [15]

Core Viewpoint - Myopia among adolescents has become a global public health issue, with over 50% prevalence in China, necessitating new intervention methods beyond existing treatments like low-concentration atropine eye drops [1][2]. Group 1: Current Challenges in Myopia Prevention - Low-concentration atropine effectively delays myopia progression by approximately 60% but only controls axial length growth by about 30%, indicating a significant limitation [2]. - The dual effects of atropine include measurement bias due to its dilation effect and a compensatory response that may lead to pathological elongation of the eyeball [2]. Group 2: Discovery of Crocetin - A groundbreaking study from Japan identified Crocetin as a potent activator of EGR-1, a key transcription factor in regulating cell proliferation and differentiation, which may intervene in myopia progression [3]. - In a mouse model, Crocetin significantly reduced axial length growth compared to the control group [5]. Group 3: Clinical Trials and Efficacy - A clinical study involving 67 children aged 6-12 showed that daily oral administration of 7.5mg Crocetin for six months resulted in a significant increase in choroidal thickness compared to the control group [8][10]. - The increase in choroidal thickness is crucial as it improves retinal metabolic conditions and inhibits scleral hypoxic expansion [10]. Group 4: Mechanisms of Action - Crocetin's effects may be attributed to multiple pathways, including EGR-1 activation, antioxidant stress response, and improved choroidal blood flow [11][13]. - Both spherical equivalent refraction and axial length measurements showed significant improvement in the Crocetin group compared to controls [12]. Group 5: Advantages and Future Prospects - Crocetin offers several advantages over traditional drugs, including its natural origin, safety for long-term use, and multi-target action addressing both axial length and refractive error [14]. - Ongoing multi-center clinical trials in China aim to validate the efficacy of different doses of Crocetin for children, with potential complementary use alongside low-concentration atropine [14]. - The development of precise drug delivery systems, such as nano-sustained release eye drops, may position Crocetin as a key player in altering the course of myopia [15].

关于公司 2025 年第一季度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据上海证券交易所《上市公司行业信息披露指引第六号——医药制造》及《关 于做好主板上市公司 2025 年第一季度报告披露工作的重要提醒》的要求，现将公 司 2025 年第一季度主要经营数据披露如下： 一、报告期内分行业经营数据 证券代码：600535 证券简称：天士力 编号：临 2025-040 号 天士力医药集团股份有限公司 1 单位：元 币种：人民币 行业 主营业务收入 主营业务成本 毛利率（%） 2025 年 1 季度 2024 年 1 季度 增长 率（%） 2025 年 1 季度 2024 年 1 季度 增长 率（%） 2025 年 1 季度 2024 年 1 季度 增长 率 医药 工业 1,841,853,945.50 1,808,711,593.51 1.83 544,797,151.33 507,143,805.22 7.42 70.42 71.96 -1.54 医药 商业 201,533,271.02 226 ...

证券代码：600479 证券简称：千金药业 公告编号：2025-029 株洲千金药业股份有限公司 | | | | | 营业 | 营业 | | | --- | --- | --- | --- | --- | --- | --- | | | | | | 收入 | 成本 | 毛利率 | | | | | 毛利 | 比上 | 比上 | 比上年 | | 分行业 | 营业收入 | 营业成本 | 率（%） | 年同 | 年同 | 同期增 | | | | | | 期增 | 期增 | 减（%） | | | | | | 减（%） | 减（%） | | | 药品生 | | | | | | 减少 | | | 530,222,497.67 | 175,258,545.39 | 66.95 | 7.21 | 11.75 | 1.34 个 | | 产 | | | | | | 百分点 | | 中药材 | | | | | | 减少 | | 及饮片 | 15,719,733.38 | 14,157,680.18 | 9.94 | -24.25 | -19.24 | 5.59 个 | | 生产 | | | | | | 百分点 | | 药品批 | | ...

今年一季度国民经济开局良好，初步核算，一季度国内生产总值318758亿元，按不变价格计算，同比增 长5.4%。除经济大省继续挑大梁交出超预期成绩外，作为西北经济版图中重要组成部分的甘肃也在今 年一季度延续此前的增长态势，多项关键经济指标增速位排全国前列。 具体看，去年四季度的增量政策开始显效，一季度基建拉动固投提升明显，传统优势产业继续承担压舱 石作用，出口方面"一带一路"共建影响逐步扩大，产业升级上新材料、数据中心建设、新能源项目以及 文旅消费目的地等成为甘肃产业焕新的主要支持力量。 根据统计，甘肃2025年一季度GDP为3118.7亿元、增长6.2%，比全国（5.4%）高0.8个百分点，增速位 排全国第3；一产、二产增加值增长6.6%、8.1%，增速分别高于全国3.1、2.2个百分点，均居全国第2； 固定资产投资增长9.9%，比全国高5.7个百分点，增速位居全国第8;进出口总值增长49.4%，高于全国 48.1%，增速为全国第2。 4月24日，粤开证券首席经济学家罗志恒对和讯分析指出甘肃一季度增速抢眼背后的三个动力因素：中 央政策大力支持，超长期特别国债"两重"项目对甘肃投资带动作用明显；自身产业竞争力优 ...

文 /高歌 之外，二季度宏观层面将要应对的另一个压力。 一季度开门红，基于当前的经济增长成果，甘肃将重大项目作为短期内的增长引擎，为实现全年既定 目标需要进一步压实基础。甘肃省二季度计划聚焦"两重""两新"领域加强重大项目谋划储备；抓住 二季度施工黄金期，加速形成更多实物工作量；规范推进政府和社会资本合作新机制，激发民间投资 活力等。 稳存量，抢增量。长期 而言 ，甘肃仍需要在产业焕新、消费回暖、培育增量等内生因素方面下足功 夫。同时抓住扩内需、稳外贸的政策机遇，在共建"一带一路"国家进出口方面承担更重要的角色。 01 "两重"项目挑大梁 去年四季度以来，一揽子增量政策开始显效扭转经济下滑趋势、推动经济企稳回升。反映至经济表 现，今年一季度国内经济总体延续了去年四季度以来的回升势头，更加积极的财政政策加码效果最为 明显。 一季度财政前置发力，结合社融数据来看，1-3月政府债净融资3.87 万亿，比2024年同期高出 2.51万亿元（其中有一些是要置换的），广义财政支持也呈现温和上升趋势。 今年一季度国民经济开局良好，初步核算，一季度国内生产总值318758亿元，按不变价格计算，同 比增长5.4%。除经济大省继 ...

Fund News Overview - 50 actively managed equity funds have reached new net asset value highs since April 8, primarily in the pharmaceutical sector, Beijing Stock Exchange funds, and emerging consumer sectors [1] - Publicly offered ETFs have significantly increased their dividend payouts, totaling 10.081 billion yuan year-to-date, representing a year-on-year growth of over 182% [1] - Insurance capital is increasingly investing in public REITs, with a notable example being the establishment of a 10 billion yuan infrastructure equity investment fund involving multiple insurance companies [1] Notable Fund Manager Activities - Liu Gesong has increased his stake in Jiangbolong, with the fund now holding 879,000 shares as of the latest quarterly report, a new addition compared to the previous year-end [2] - Zhu Shaoxing has reduced his holdings in Weiteng Electric from 6.0067 million shares at the end of last year to 1.5 million shares as of the latest quarterly report, a decrease of 4.5067 million shares [2] ETF Market Commentary - The market experienced a slight decline with the Shanghai Composite Index down by 0.2%, and the Shenzhen Component Index down by 0.62%. The total trading volume in the two markets was 1.06 trillion yuan, a decrease of 57.2 billion yuan from the previous trading day [3] - The gaming sector ETFs showed positive performance, with the leading gaming ETF rising by 1.52% [3] ETF Thematic Opportunities - The State Council has approved a plan to accelerate the opening of the service industry, highlighting 155 pilot tasks, including a focus on the international expansion of the gaming industry. This presents potential investment opportunities in gaming ETFs [6] Upcoming Fund Launches - The Huatai-PineBridge Hang Seng Consumer ETF is set to launch, managed by Li Muyang, with a performance benchmark based on the Hang Seng Consumer Index [7]

金 融 期 货 研 究 | 期指：关注今日发布会 毛磊 | | 投资咨询从业资格号：Z0011222 | | | maolei@gtht.com | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 【期指期现数据跟踪】 | | | | | | | | | | | 期指数据 | | | | | | | | | | | 收盘价 涨跌幅% 成交额-亿 | 基 差 | | 成交量 | 变 | | 动 | 动 | 持仓量 | 变 | | | 收盘价 | 涨跌幅% | 基 差 | 成交额-亿 | 成交量 | 变 动 | 持仓量 | 变 动 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 沪深300 | 3786.99 | ↑0.07 | | 2205.4 | | | | | | IF2505 | 3774.8 | ↑0.14 | -12.19 | 282.3 | 24910 | ↑984 | 48945 | ↓1234 | | IF2506 | 3739. ...